Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in TNF-IR Plaque Psoriasis
NCT01961609Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2013
- Primary completion
- Jul 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of secukinumab in plaque psoriasis, sponsored by Novartis. Started Oct 2013; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT01961609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01961609.